our results suggest that miR-21, miR-205, miR-30d, and miR-24 may serve as potential novel non-invasive biomarkers for diagnosis of lung cancer

High miR-205 expression is associated with malignant phenotypes in non-small cell lung cancer.

The relative expressions of miR-205-5p, miR-205-3p, and miR-21-3p in tissues and serum among non-small cell lung carcinoma (NSCLC) patients, were assessed.

Our results demonstrated that miR-205 is involved in the tumorigenesis of Non-small cell lung cancer through modulation of the PTEN signaling pathway.

Levels of MiR-205 distinguishes squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

MiR-205/miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and survivin signaling in lung cancer cells.

PTEN is a direct target of MIR205 in lung cancer tissue. MIR205 might inhibit lung cancer cell proliferation by regulating PTEN expression.

Low miR205 expression is associated with small cell lung cancer.

A polymorphism, rs3842530, located downstream of the miR-205 gene and in the fourth exon of the miR-205 host gene (miR-205HG), was screened. rs3842530 had no correlation with the risk of breast cancer, but was associated with the risk of lung cancer (P<0.05)

miRNA-205 might serve as a potential biomarker for the prognosis of advanced non-small cell lung cancer.

Data indicate that miR-9, miR-16, miR-205 and miR-486 may serve as non-small cell lung cancer (NSCLC) biomarkers.

MIR205HG acts as a ceRNA to expedite cell proliferation and progression in lung squamous cell carcinoma via targeting miR-299-3p/MAP3K2 axis.